Yen-Ming Hsu

This inventor holds 26 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Immunology Research. Top assignees: Biogen Idec Ma Inc., Biogen, Incorporated, Biogen Ma Inc.. Active years: 1997-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yen-Ming Hsu. Retrieved from https://idiyas.com/inventor/yen-ming-hsu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 10)

% Patents Active = 80.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.1

ph-index = 6

Forward Citations = 166(Granted Patents)

Location History:

Lexington, MA (US) (1997 - 2022)
Concord, MA (US) (2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

Areas of Expertise:

Recombinant Immunoglobulin

BAFF Antagonists

Anti-BCMA Antibodies

CD40L-binding Agents

Platelet Aggregation Assays

Truncated BAFF Receptors

Binding Proteins

Antibody Derivatives

Immunological Disorders

CAIP-like Gene Family

Evaluating BAFF

Binding Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11801286 - Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use (2023-10-31),

2. 11304994 - Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use (2022-04-19),

3. 11111307 - Anti-BCMA antibodies (2021-09-07),

4. 9494597 - Human control antibodies and uses therefor (2016-11-15),

5. 9321840 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2016-04-26),

6. 9297810 - CD40L-binding agent based platelet aggregation assays (2016-03-29),

7. 9097726 - Methods of evaluating BAFF (2015-08-04),

8. 9034324 - Anti-BCMA antibodies (2015-05-19),

9. 8821883 - Method of treating B cell cancers by administering truncated BAFF receptors (2014-09-02),

10. 8784823 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2014-07-22),

11. 8685657 - Methods of evaluating BAFF (2014-04-01),

12. 8617545 - Methods for use with BAFF antagonists (2013-12-31),

13. 8415111 - Methods of evaluating BAFF (2013-04-09),

14. 8409810 - Platelet aggregation assays using a CD40L-binding agent (2013-04-02),

15. 8303958 - Method of treating immunological disorders by administering truncated BAFF receptors (2012-11-06),

Sure, I can help you with that! Here is a bio of inventor Yen-Ming Hsu:

Title: Innovator Spotlight: Yen-Ming Hsu - Revolutionizing Immunotherapy

Introduction:

Yen-Ming Hsu, a brilliant inventor based in Lexington, MA (US), has made significant contributions to the field of immunotherapy with his groundbreaking patents and research.

Latest Patents:

Yen-Ming Hsu's latest patents focus on Recombinant Intravenous Immunoglobulin (rIVIG) compositions and methods for their production and use. These compositions feature oligomeric Fc molecules that exhibit high avidity for Fc receptors. The rIVIG proteins have shown promise in treating a wide range of immune disorders, from autoimmune diseases like lupus and multiple sclerosis to immune-mediated conditions in both humans and animals.

Career Highlights:

Yen-Ming Hsu's illustrious career includes a total of 26 patents to his name. He has been a key figure at companies like Biogen Idec MA Inc. and Biogen, Incorporated, where his innovative work has helped shape the future of immunotherapy.

Collaborations:

Throughout his career, Yen-Ming Hsu has collaborated with esteemed professionals in the field. Some of his notable coworkers include Susan L Kalled and Lihe Su, who have contributed to the success of his projects and patents.

Conclusion:

In conclusion, Yen-Ming Hsu's inventive spirit and dedication to advancing immunotherapy have led to remarkable breakthroughs in the treatment of various immune disorders. His work continues to inspire and pave the way for further innovations in the field.

Profile summary based on public USPTO records.